MRPL41

Across TCGA pan-cancer cohorts, MRPL41 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MRPL41 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher MRPL41 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL41 expression acts as an unfavorable survival marker.

THCA and PRAD are the cancer types where MRPL41 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.178	0.952	<.001	21	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MRPL41–THCA (OS)

Open the THCA breakdown →